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ABSTRACT 
Recombinant bovine intercellular adhesion molecule-I (ICAM-1) has potential as an 
anti-inflammatory agent for treating bovine mastitis and other inflammatory conditions. The 
objective of this study was to produce biologically active recombinant bovine ICAM-1 in order 
to investigate its use as a potential immunomodulator. Using a cDNA encoding the complete 
bovine ICAM-1 open reading frame, polymerase chain reaction (PCR) was used to prepare 
cDNAs encoding domains 1 and 2 (Bl), or domains 1 through 5 (A6), of bovine ICAM-1. 
These were cloned into the pTrxFus expression vector down stream and in frame with the 
sequence coding for the expression tag, thioredoxin. The constructs were verified by DNA 
sequence analysis. The E. coli strain GI724 was transformed with the constructs and 
expression of the recombinant protein was induced by tryptophan. The ICAM-1 (domains 1 
and 2 or 1-5) constructs were mainly expressed as insoluble protein in inclusion bodies, with 
little recombinant protein in the soluble fraction of cell lysates. The recombinant protein was 
identified by Western blots using a mAb to the thioredoxin tag. The inclusion bodies were 
solubilized by the addition of 6 M guanidine-HCl. Guanidine-HCl was then slowly removed 
by dialysis, and the recombinant protein was partially purified by ion exchange chromatography 
using DEAE Sephacel. Recombinant protein from the soluble portion of the cell lysates was 
used to immunize mice in attempts to obtain a mouse mAb to recombinant bovine ICAM-1. 
Preliminary data using flow cytometry showed differential binding between normal and ~2 




This thesis is organized in a standard format consisting of six chapters: a General 
Introduction, Literature Review, Material and Methods, Results, Discussion, and Conclusions. 
The General Introduction consists of a review of the literature of leukocyte trafficking with 
emphasis on the intercellular adhesion molecules. The remaining chapters outline and detail the 
means by which the goals of this project were addressed. 
Literature Review 
Leukocytes play a key role in the surveillance of tissues for pathogens and tissue injury. 
The nature of the inflammatory stimulus, the location of the insult, and the surface molecules 
present on various leukocytes determine the subpopulation of cells that interact with the 
endothelium [1] . Generally, neutrophils are the first line of defense in an inflammatory 
response [2, 3, 4]. Though an inflammatory response is needed to fight infection, leukocytes, 
and particularly neutrophils, can cause extensive tissue damage in the host [2, 5, 6]. This can 
occur in adult respiratory distress syndrome in humans, bovine respiratory disease complex in 
cattle, and mastitis in both humans and animals [7, 8, 9] . Sometimes it is necessary to limit an 
immune response to lessen the severity of damage host cells may cause while mounting an 
effective immune response. 
Immune cells adhere to one another and to other cells using four families of adhesion 
proteins: the selectin, cadherin, integrin, and immunoglobulin, families [10, 11 , 12]. 
Chemoattractants including but not limited to interleukin-8 (IL-8), RANTES (Regulated Upon 
Activation, Normal T cell Expressed and Secreted), macrophage chemotactic protein 1 (MCP-1), 
and bacterial N-formyl peptides aid in directing leukocytes to sites of infection and tissue 
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injury [I, 2]. Subsequent leukocyte extravasation into sites of infection induces a multi-step 
process involving the four families of adhesion proteins and chemoattractants. 
Extravasation includes the steps of leukocyte rolling, tight binding, diapedesis, 
(movement of leukocytes between the endothelial cell junctions) and lastly migration to sites of 
infection [4, 6, 13, 14]. Leukocytes roll along the endothelial lining of blood vessels under the 
shear force of blood flow [I, 2, 3, 6]. A transient rolling or "sticking" is accomplished by 
carbohydrate ligands on leukocytes binding with E-selectin and P-selectin on the surface of 
endothelial cells, and L-selectin on leukocytes adhering to its carbohydrate ligand on endothelial 
cells [I, 13, 15]. This transient interaction is reversible within seconds and is not sufficient to 
allow white blood cells to remain bound to the vessel wall without further activation of 
accessory molecules [13] . 
Activation of leukocytes by chemoattractants and cytokines can trigger tight adhesion of 
leukocytes already tethered to the endothelial lining of blood vessels [2, 13]. This is facilitated 
by the activation of the B2 integrins, specifically LFA-1 and Mac-I on the surface of white 
blood cells interacting with their ligand, intercellular adhesion molecule-I (ICAM-1) on 
endothelial cells [2, 13]. The LFA-1 / ICAM-1 interaction is sufficient to cause leukocyte arrest 
at sites of infection even under the shear force of the blood flow. This interaction, however, is 
still reversible within minutes [4, 15]. 
Diapedesis is dependent on glycosylated aminoglycans and the B2 integrins on the 
leukocyte plasma membrane adhering to platelet endothelial cell adhesion molecule-I (PECAM-
1, CD31) at the intercellular junctions of endothelial cells [2, 3, 6, 15]. These interactions allow 
the leukocyte to squeeze between the endothelial cells, thereby leaving the blood vessel and 
entering into sites of injury [15, 16]. 
The last step in the extravasation process, leukocyte migration to specific sites of 
infection within the tissue matrix, is facilitated by the chemotactic gradient generated by 
chemoattractants, and integrins binding to selected extracellular matrix proteins [I, 3]. 
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Leukocyte extravasation can be regulated at the various steps in the process, thus modulating the 
inflammatory response. Selectivity in the process of leukocyte recruitment to sites of tissue 
injury comes from the diversity of molecules capable of mediating each step [1, 14]. 
The goal of this research was to produce a biologically active form of recombinant 
bovine Intercellular Adhesion Molecule-1 (rbICAM-1) in a prokaryotic expression system, and 
produce a monoclonal antibody (mAb) against bovine ICAM-1. The rationale behind these 
goals was as follows : the recombinant protein could be used as an immunomodulator in vivo, 
and in vitro for the detection of surface molecules present on bovine endothelial cells and 
leukocytes. These surface molecules would include the ligands for ICAM-1, the ~2 integrins. 
The rbICAM-1 could also be used to detect ICAM-1 expression in bovine tissue in vitro, and as 
an immunomodulator in vivo. This is the first report of the production of biologically active 
rbICAM-1. 
Adhesion Molecules In Leukocyte Trafficking 
The Selectins 
The selectin family of adhesion proteins mediates the initial role in leukocyte 
recruitment to sites of infection [2, 4, 13]. They are involved in the initial tethering and rolling 
of leukocytes along postcapillary venule endothelial cells lining the vessel walls. The adhesive 
proteins L-selectin (CD62L), E-selectin (CD62E), and P-selectin (CD62P) are the selectin 
molecules involved and are named after cells on which they were first identified [2, 3, 4, 17, 18]. 
L-selectin was discovered on lymphocytes, and has been found on all circulating leukocytes, 
except for a subpopulation of memory lymphocytes [1, 2] . 
E-selectin was first found on endothelial cells, but only after stimulation by 
inflammatory cytokines [1, 2, 17]. P-selectin was first discovered preformed, stored in the 
a granules of platelets, and in the Weibal-Palade bodies of endothelial cells [1, 2, 3, 17]. It is 
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rapidly mobilized to the plasma membrane in response to mediators of inflammation such as 
thrombin and histamine [l, 2], [3]. 
In contrast to L- and P-selectin, E-selectin is the only selectin that requires de novo 
synthesis [1]. All three selectins are involved in the recruitment of leukocytes, but there are 
fundamental differences in their distribution, activation, and mode of expression [16]. 
The three members of the selectin family are all transmembrane glycoproteins that 
possess a carbohydrate-recognizing domain (CRD) at their amino terminus, an epidermal 
growth factor (EGF)-like domain, and two (L-selectin), six (E-selectin), or nine (P-selectin) 
complement regulatory domains [15, 16]. There is also a transmembrane segment and a short 
cytoplasmic domain [2, 16, 17]. The CRD at the amino terminus end of the selectins is 
homologus to the Ca2+ dependent (C-type) lectins [l, 16]. 
The level of homology among the three selectins is 60-65% at the CRD and 40-45% at 
the EGF-like domain [2, 16]. There is little homology among the three in the transmembrane 
and cytoplasmic domains [15, 16]. The lectin domain plays the most crucial role in ligand 
binding. This domain mediates cell-cell contact through Ca2+-dependent interactions with cell-
surface carbohydrates [1, 15, 16]. 
All selectins recognize a sialylated carbohydrate moiety on their counterreceptors. E 
and P selectin recognize carbohydrate structures that are distinct, but closely related to the 
tetrasaccharide sialyl Lewisx and its isomer sialyl Lewis" [1, 3, 15, 16]. A high affinity ligand 
for P-selectin, termed P-selectin glycoprotein ligand-1 (PSGL-1) has been characterized [1, 3, 
12, 16]. PSGL-1 also serves as a counterreceptor for E-selectin [16]. PSGL-1 is expressed on 
all blood neutrophils, monocytes, and lymphocytes [l, 16]. Another glycoprotein ligand has 
been identified specific for E-selectin, E-selectin ligand-1 (ESL-1) [ 16]. 
The ligand for L-selectin is also related to the Lewisx,a moieties, but contains sialic acid 
and sulfate as well [1, 15]. Two sulfated glycoprotein ligands have been identified for L-
selectin. The first one, termed glycosylation dependent cell adhesion molecule-1 (GlyCAM-1), 
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is expressed mainly by the endothelial cells of high endothelial venules (HEVs) of lymphoid 
tissue, and can be secreted into the blood stream as well [l, 2, 15, 16]. The second, termed 
peripheral node addressin (PNAd, CD34), is expressed by the endothelial cells of many tissues 
as well as hemapoietic stem cells [l, 2, 15, 16]. 
Binding of the selectins to their ligands is transient and reversible in seconds under the 
shear force of blood flow (i.e., rolling) [4, 13]. Leukocytes roll along the endothelial lining of 
the vasculature as part of their immunosurveillance. L-selectin on the tips of the leukocyte 
microvilli transiently binds with its receptors GlyCAM-1 or CD34, and without further 
activation, detach and re-enter the circulation to roll elsewhere along the vasculature [15]. L-
selectin expression on leukocytes is plentiful, especially on unactivated leukocytes [15]. 
The importance of the carbohydrate moieties on the selectin ligands for adhesion is 
made evident by the genetic disease leukocyte adhesion deficiency type II (LAD II). In 1992 
Etzioni et al. identified two unrelated children with neutrophilia, recurrent bacterial infections, 
and failure of their neutrophils to bind cytokine-activated endothelial cells [19]. The patients 
also exhibited short stature and mental retardation [19]. Further in vitro analysis of leukocytes 
from these patients revealed they failed to express the sialyl Lewisx structure and therefore are 
unable to bind E-selectin and P-selectin [19]. Etzioni et al. (1992) reported this disorder as 
LAD II. Consistent with the proposed role of selectins in extravasation, leukocytes from these 
individuals fail to roll along cytokine activated endothelial cells of postcapillary venules. 
Furthermore, these individuals suffer from recurrent bacterial infections, fail to form pus, and 
exhibit short stature and mental retardation due a disorder in fucose metabolism [4, 12]. Fucose 
is an important component of sialyl Lewisx. 
During an inflammatory response, cytokines and chemoattractants present at sites of 
infection activate leukocytes and the surrounding vascular endothelial tissue. E-selectin and P-
selectin expression is upregulated as well as their ligands. This also includes a rapid up 
regulation of L-selectin on leukocytes, followed by its down regulation [14, 15, 16]. During 
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this activation process, L-selectin is shed and receptors for the selected proinflammatory 
cytokines and chemoattractants on leukocytes are upregulated. This activation process along 
with vasodilation leads to an accumulation of leukocytes at the site of tissue injury. 
The lntegrins 
Another family of adhesive proteins permits leukocyte arrest and stops the transient 
flow of white blood cells at sites of inflammation and tissue injury. This class is termed the 
integrins. Integrin proteins are involved in the integration of cells with the extracellular matrix, 
hence the name integrin [10, 20]. The integrin superfamily consists of more than 20 
structurally homologous proteins that promote cell-cell or cell-matrix interactions [3, 21]. 
These interactions are a basic component of cell migration and recognition, and underlie many 
biologic processes, including embryogensis, tissue repair, and immune and inflammatory 
responses [12, 21]. 
The integrins are composed of non-covalently linked a and 13 chains selected from 
among 17 a and 8 13 subunits that heterodimerize to produce various receptors[lO]. Three 
major groups of integrins, /3i, /32 and the /37 subfamilies are important in the interactions of 
leukocytes with endothelium [l, 15]. 
In the !31 subfamily the a4/3 1 integrin is an important adhesion molecule based on its 
interaction with vascular cell adhesion molecule-I (VCAM-1), found on activated endothelium 
at sites of inflammation [1, 15]. The !32 integrin subfamily consists of LFA-1 (CD11a/CD18), 
Mac-1 (CD11b/CD18), p150,95 (CD11c/CD18), and act/32 (CD11d/CD18) [15]. The third 
subfamily, /37, includes an important member, the a4 /37 integrin. This integrin is important in 
1 ymphocyte-endothelium interactions [ 15]. 
The integrin molecules can be found on various subpopulations of leukocytes. The 
integrin expressed depends on the individual leukocyte and its state of activation. The /32 
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integrin subfamily interacts with intercellular adhesion molecules (ICAMs), specifically ICAM-
1, 2, and 3 [22]. 
LFA-1, Mac-1, and p150,95 (though less characterized) are the ~2 integrins that play a 
major role in leukocyte adherence to activated endothelium via the ICAMs [23, 24]. They 
contain different a chains (CD 1 la,b,c, and d) but possess a common ~ chain, CD 18 [11, 23, 
25]. The globular heads of the a subunits of the ~2 integrins contain an "I" (inserted) domain 
not seen in many integrins [2]. The I domain is a 200 amino acid sequence at the N terminus of 
the a chain [25]. The I domain contains bivalent cation-binding sites that are essential for 
ligand binding [2, 26]. Mg2+ and Ca2+ are the two essential cations that mediate ligand binding 
and the activation state of the integrins [1, 27]. 
LFA-1 is found on Band T lymphocytes, monocytes and neutrophils [2, 28]. Upon 
activation, LFA-1 can selectively bind ICAM-1, -2, or-3 [29, 30, 31]. Mac-1 is expressed by 
monocytes, neutrophils, and some mast cells and natural killer cells (NK cells) [2, 18]. Mac-1 
is able to bind ICAM-1, ICAM-2, fibrinogen, and the complement opsonin iC3b [18, 22, 32]. 
p150,95 is found on monocytes, neutrophils, natural killer cells, and platelets [18, 33]. Upon 
activation p150,95 is able to bind fibrinogen and the complement opsonin iC3b [18, 24]. 
Activated cells expressing p150,95 are able to bind stimulated endothelial cells, with the 
postulated ligand being ICAM-1 [24]. 
The ~2 integrins are mainly activated by a process termed "inside-out" signaling [30]. 
That is, intracellular signals that activate (produce conformational changes) first in the 
cytoplasmic domains, and then in the extracellular portion of the integrin heterodimers are only 
triggered once an accessory molecule on the leukocyte has bound its ligand [22, 30, 34]. The 
best example of inside-out signaling to activate LFA-1 is found in peripheral blood 
lymphocytes (PBLs). 
Circulating PBLs generally express an inactive form of LFA-1 [30, 34]. This is crucial 
in maintaining homeostasis, since constitutively active LFA-1 would cause aggregation of 
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circulating cells and clogging of the blood vessels [30]. Intracellular signals that activate LFA-1 
are generated only after activation of a lymphocyte mainly by the T-cell receptor TCR/CD3 
complex [30, 34, 35]. In addition to the TCR/CD3 complex, several other leukocyte receptors 
can activate LFA-1 through the G proteins or protein tyrosine kinases [15, 30, 36]. The 
quantity of intracellular divalent cations, specifically Mg2+, Ca2+, and Mn2+ present in the 
microenvironment of the cytoplasmic tail of the integrin also plays a critical role in the 
activation/deactivation process [18, 22, 30]. 
The importance of the ~2 integrins in mounting an effective immune response is made 
evident by the genetic disease leukocyte adhesion deficiency type I (LAD I) identified in 
humans [28] dogs [37] and bovine leukocyte adhesion deficiency (BLAD) in cattle [38] [39]. 
Humans and animals afflicted with these diseases have various genetic defects in the CD18 
molecule of the ~2 integrin heterodimer [28, 39]. Leukocytes from LAD I patients are able to 
roll along the blood vessel wall, but are unable to arrest at sites of infection [28], [4, 38]. This 
leads to leukocytosis and the threat of death from recurrent infections [28, 40]. Humans 
afflicted with the severe form of LAD I (no CD 18 expression) die at childhood [ 4, 28] and 
BLAD animals rarely survive past nine months of age [38, 39, 41]. 
Intercellular Adhesion Molecules 
Intercellular adhesion molecules (ICAMs) are Type I transmembrane glycoproteins that 
belong to the immunoglobulin gene superfarnily [20, 42, 43]. Their cellular distribution, degree 
of glycosylation, and molecular weights vary [20, 44, 45]. ICAMs promote adhesion of 
immune cells to the extracellular matrix and aid in the interactions between antigen presenting 
cells (APCs) and lymphocytes during immunological and inflammatory reactions by binding 
their ligand, the f32 integrins [11, 43, 46, 47]. There are currently five members in the ICAM 
family including three that have been identified with respect to leukocyte trafficking: ICAM-1, 
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ICAM-2, and ICAM-3 [11, 20], [22, 45]. The role ofICAM-1 in leukocyte adherence and 
extravasation has led to it being targeted as an anti-inflammatory agent [6, 48, 49]. 
ICAM-1 
ICAM-1 is the most widely distributed intercellular adhesion molecule and is the most 
extensively studied molecule in the ICAM family [22]. At the Leukocyte Typing Workshop IV 
(Vienna, Austria 1989) it was given the cluster of differentiation (CD) designation of CD54 
[50]. It is expressed constitutively on the surface of endothelial cells, T and B lymphocytes, 
monocytes, dendritic cells, and epithelial cells at low levels [11] [47] [50] [43]. These cells 
upregulate their expression of ICAM-1 in the presence of proinflammatory cytokines including 
IL-1 (interleukin-I) and tumor necrosis factor alpha (TNF a) [11, 43, 50]. Recent evidence 
indicates that ICAM-1 belongs to the family of acute-phase response genes which are induced 
by interleukin-6 (IL-6) [51]. 
The upregulation of ICAM-1 by proinflammatory cytokines occurs in a cell type 
specific manner [50]. ICAM-1 surface expression on T cells is upregulated by interleukin-2 
(IL-2) and to a lesser extent by gamma interferon (IFN-y) [50]. In contrast, IFN-y, TNF a, and 
IL-1 are all good inducers of ICAM-1 on fibroblasts. Endothelial cells increase their surface 
expression of ICAM-1 in response to TNF a, lymphotoxin, and IL-1, with a less potent 
response from IFN-y [50]. Increased ICAM-1 surface expression can be detected within four 
hours of stimulation of the various cell types, and expression is often maintained for greater 
than twenty-four hours [14, 50]. 
The key role ofICAM-1 in the inflammatory process is to promote leukocyte arrest 
under the shear force of the blood flow by binding its ligand (the ~2 integrins) found on all 
leukocytes. This binding stops leukocyte rolling at sites of infection for subsequent 
transendothelial migration [6, 13, 45]. ICAM-1 has been cloned and sequenced in humans, 
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chimpanzee, murine, rat, canine, and the bovine [43, 52, 53, 54, 55]. Among these species there 
is 55-65% homology at the DNA level [43]. 
ICAM-1 Structure 
The human ICAM-1 gene consists of seven exons separated by six intrans [51]. 
Studies of ICAM-1 cDNA have led to its structural and functional analysis, including its 
identification as a member of the immunoglobulin superfamily [42]. The 5' -flanking region of 
the ICAM-1 gene contains binding sites for many transcription factors. These include the 
glucocorticoid receptor binding sites, IFN-y- responsive elements, NF-KB (Nuclear Factor-KB) 
consensus elements and AP-1 and -2 (Activator Protein) can be found in this region [51, 56]. 
ICAM-1 contains five extracellular immunoglobulin-like domains and varies in 
molecular weight from 80-115 kilodaltons (kDa) depending on the degree of glycosylation 
[42]. The five extracellular domains oflCAM-1 are each encoded by their own exon [51]. The 
immunoglobulin-like domains are comprised of 453 predominantly hydrophobic amino acids, 
followed by a hydrophobic transmembrane domain, and a short charged cytoplasmic tail [43]. 
Domains one through four contain 88, 97, 99, and 101 amino acid residues respectively, which 
are typical of immunoglobulin domain size; domain five is truncated with 68 amino acid 
residues [42]. The extracellular immunoglobulin-like domains contain a B sheet structure 
which is stabilized by disulfide bridges between highly conserved cysteine residues in domains 
one, two, three, and five [42, 43]. 
It was originally hypothesized that ICAM-1 was a monomeric protein [42]. Further 
experimental analysis proved that membrane bound ICAM-1 is indeed a homodimer with 
greater affinity and avidity for its ligand, the B2 integrins, versus monomeric ICAM-1 [57, 58, 
59]. The exact mechanism leading to homodimer formation of ICAM-1 has yet to be 
elucidated. 
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ICAM-1 and Ligand Binding 
As mentioned previously ICAM-1 binds the B2 integrins LFA-1 and Mac-1. Many 
integrins that bind extracellular matrix proteins bind to a calcium binding RGD (Arg-Gly-Asp) 
sequence in their ligand [60]. Human ICAM-1 is the first identified ligand for the integrins that 
does not contain a calcium binding RGD sequence [43, 60]. In addition, ICAM-1 serves as the 
receptor for a major group of human rhinoviruses (at least 90% of the approximately 100 
identified serotypes), the causative agent of the common cold [61, 62, 63]. It is also the ligand 
for Plasmodiumfalciparum on erythrocytes, the pathogen responsible for malaria [64]. 
Upon activation, the B2 integrins undergo an extracellular conformational change 
enabling them to bind to ICAM-1 (see above). Mutational analysis of the cDNA encoding 
ICAM-1 has revealed that the LFA-1 binding site is located in domain one [60, 65] . 
Glycosylation of domain one is not essential to ICAM-1/LFA-1 binding as none of the 8 
potential glycosylation sites in ICAM-1 are located in domain 1 [42]. In vitro analysis of 
monomeric vs. dimeric ICAM-1 binding to LFA-1 revealed that the homodimer form has a 
higher degree of binding to LFA-1 [57, 58]. 
The binding site for Mac-1 is located in the third immunoglobulin-like domain of 
ICAM-1 [46]. Mutational analysis of the cDNA encoding human ICAM-1 demonstrated that 
the degree of glycosylation in domain three affected Mac-1 binding. Amino acid substitutions 
that eliminated the N-linked glycosylation sites in domain three ofICAM-1 resulted in higher 
affinity binding of Mac-1 compared to wild type ICAM-1 [46]. 
The ICAM-1 LFA-1/Mac-1 interaction is a key step in leukocyte trafficking and the 
generation of an immune response. The interactions of these molecules not only causes 
leukocyte arrest at sites of inflammation but aids in facilitating T-cell mediated killing, T-helper 
and B-lymphocyte responses, killing by Natural Killer cells (NK), and antibody-dependent cell 
mediated cytotoxicity [43, 46, 66, 67]. Antibodies against LFA-1 and Mac-1 have been shown 
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to limit or abrogate the inflammatory response emphasizing the importance of the ICAM-1 
LFA-1/Mac-l interaction [23, 24, 43, 66] . 
Domain one of human ICAM-1 serves as the major receptor for rhinoviruses [42, 63] . 
Mutagensis of the cDNA encoding human ICAM-1 showed that glycosylation is not required 
for rhinovirus attachment [60, 63]. Truncated forms of ICAM-1 lacking domains 3,4, and 5 
were able to bind rhinoviruses but to a lesser extent (10 fold decrease) than wild type ICAM-1 
[60, 63]. Domains 3-5 oflCAM-1 may play a role in virus binding by enhancing the tertiary 
structure of the first two domains by allowing greater accessibility to the virus receptor site in 
domain 1. Rhinoviruses are able to bind recombinant monomeric and dimeric ICAM-1 in vitro, 
but exhibit a higher affinity for the dimeric form [58]. Attachment of human rhinoviruses to 
human ICAM-1 is species specific. Cells from other species, which express host ICAM-1 , are 
not able to bind human rhinovirus [63]. 
The primary event in the pathogenesis of malaria is the attachment of Plasmodium 
falciparum-infected erythrocytes to at least three different receptors on capillary endothelium 
[64, 68]. Berendt et al. (1989) identified human ICAM-1 as one of these receptors. The other 
two receptors are glycoprotein IV (CD36) and thromobospondin [64]. Mutagenesis of 
hICAM-1 cDNA revealed that the binding site for P. falciparium-infected erythrocytes is 
located in domain one of ICAM-1 [69]. Attachment of infected red blood cells to hICAM-1 
seems to be species specific as infected erythrocytes do not bind murine ICAM-1 in vitro [68]. 
Murine ICAM-1 has 50% homology to human ICAM-1 at the amino acid level [53] and, 
therefore, may not have receptors for infected erythrocytes. 
Though LFA-1, human rhinovirus, and P.falciparum-infected erythrocytes are able to 
bind domain one oflCAM-1, their respective binding sites are distinct with only a small degree 
of overlap (60, 68, 69]. Monoclonal antibodies against ICAM-1 which block the LFA-
1/ICAM-1 interaction do not inhibit human rhinoviruses and infected erythrocytes from binding 
to ICAM-1 in vitro [68, 69] . Treatment of ICAM-1 with a different set of monoclonal 
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antibodies is required to disrupt ICAM-1 binding to human rhinovirus and infected 
erythrocytes [68, 69] . 
ICAM-1 has also been implicated as a receptor for fibrinogen, sialophorin (CD43), and 
the matrix factor hyaluronan [43, 70, 71]. The extent these proteins interact with ICAM-1 
during ICAM-1 cell mediated adhesion has not been determined. 
Bovine ICAM-1 
In 1997 bovine ICAM-1 was cloned and sequenced by Lee et al. Sequence comparison 
with ICAM-1 from other species aligns bovine ICAM-1 in the lg superfamily. The open 
reading frame of 1605 nucleotides encodes 535 amino acids that include a signal sequence, five 
extracellular lg-like domains, a hydrophobic transmembrane region, and a cytoplasmic tail [72]. 
There are 13 potential N-glycosylation sites in bovine ICAM-1 [72]. Unstimulated bovine 
mononuclear cells and neutrophils exhibit low and undetectable levels of ICAM-1 mRNA 
respectively [72]. Upon stimulation with inflammatory mediators these cells have an increase in 
total ICAM-1 mRNA [72]. 
At the amino acid level bovine ICAM-1 exhibits 57% homology with human ICAM-1 
with the greatest degree of homology existing in domain two (70%) [72]. Like the typical 
integrin ligand, bovine ICAM-1 contains the calcium binding RGD sequences in its 
extracellular domains [72]. 
Therapeutic Uses of Recombinant ICAM-1 (rlCAM-1) or an ICAM-1 Monoclonal 
Antibody 
The recognition that cell adhesion (cell-cell, and cell-matrix) plays an important role in 
the inflammatory process has raised the prospect of using therapeutic intervention in certain 
cases of acute and chronic inflammation. Leukocyte adhesion can be inhibited by mAbs to 
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adhesion molecules or using recombinant forms of leukocyte receptors. It is well documented 
that antibodies to the B2 integrins can block leukocyte adhesion in vitro and in vivo [23, 31, 66]. 
Recently the use of ICAM-1 mAbs and rICAM-1 to block leukocyte adhesion has been 
investigated. Preliminary investigations into blocking the ICAM-1/LFA-1 interaction assessed 
the role that this binding plays in exacerbating immune induced complications. These would 
include the role of ICAM-1 in ischemia-reperfusion injury, allograft rejection, and in chronic 
inflammation such as rheumatoid arthritis. The use of rICAM-1 has also been investigated in 
attempts to block rhinovirus attachment in vivo [73]. 
Antibodies to ICAM-1 have been shown to inhibit both lymphocyte and granulocyte 
adhesion processes in in vitro assays including mixed lymphocyte reactions, cytotoxic T-cell 
activity, and granulocyte and lymphocyte attachment to endothelium [47, 49]. In vivo testing 
has yielded promising results in treating inflammatory disorders [6, 49, 73]. 
The leukocyte cell adhesion cascade plays a critical role in myocardial ischemia-
reperfusion injury. Reperfusion of ischemic tissue leads to an upregulation of inflammatory 
mediators and an influx of leukocytes to the coronary microvasculature [6, 74]. Neutrophils are 
the predominant leukocyte implicated in myocardial ischemic-reperfusion injury. During 
ischemia, inflammatory mediators are released into the coronary vasculature. Upon reperfusion 
neutrophils are recruited to this area and view the ischemic tissue as foreign. This process 
exerts a greater damage to the myocardium contributing to necrosis of cardiac tissue than would 
occur by ischemia alone (i.e., reperfusion itself may exacerbate the injury sustained during the 
ischemic period) [6, 74]. 
The ICAM-1/LFA interaction is a key step in the adherence of neutrophils to the 
coronary vasculature. Depletion of circulatory leukocytes or reperfusion in the absence of 
neutrophils markedly attenuates the degree of reperfusion injury [6, 74, 75]. In a feline model 
of reperfusion injury, administration of mAbs to ICAM-1 greatly reduced myocardial infarct 
size as compared to control animals [6]. In rat and rabbit models an even greater difference was 
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seen using mAbs to ICAM-1 in reducing the severity of myocardial ischemia-reperfusion injury 
[6, 75]. 
In human studies, administration of a mAb to ICAM-1 greatly improved allograft 
survival in renal and liver transplants [6, 49]. For patients with rheumatoid arthritis, chronic 
inflammation in the joints was reduced by treatment with a mAb to ICAM-1 compared to 
controls [49, 76, 77] . 
The therapeutic use of a recombinant form of human ICAM-1 has been investigated for 
treating rhinovirus infection. 'Tremacamra' a recombinant soluble form ofICAM-1 produced 
by Boehringer Ingelheim Pharmaceuticals Inc. (Ridgefield, CT) was used in an experimental 
rhinovirus infection model [73]. This experiment yielded promising results as subjects given 
Tremacamra intranasally exhibited less symptoms of the common cold (e.g. nasal congestion, 
cough, sneezing, and sore throat), yielded lower virus titers, and had lower nasal mucus weights 
versus the control group [73]. 
ICAM-2 
ICAM-2 was discovered when it became apparent that antibodies to ICAM-1 did not 
block all LFA-1 dependent adhesions in vitro, thus suggesting there was a second LFA-1 ligand 
[78, 79, 80]. ICAM-2 is a cell surface protein with a broad distribution, being constitutively 
expressed on platelets, T and B lymphocytes, monocytes, and to a higher degree on vascular 
endothelial cells [81 , 82, 83]. It is not expressed on neutrophils [82]. 
ICAM-2 is given the CD designation of CD102 [83] and has not been as extensively 
characterized as ICAM-1. Studies on cells bearing surface expression ofICAM-2 reveal that it 
is not upregulated by proinflammatory cytokines or other mediators of inflammation [78, 80, 
82, 84]. ICAM-2 has been cloned and sequenced in humans and mice [78, 84]. 
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ICAM-2 Structure 
The ICAM-2 gene contains five exons, two of which encode the extracellular lg-
domains [ 44]. The remaining three exons encode the signal sequence, the transmembrane 
segment, and the cytoplasmic tail [44] . ICAM-2 has a molecular weight of 46 - 65 kDa 
depending on the degree of glycosylation [78, 81 , 82]. There are six potential N-linked 
glycosylation sites in ICAM-2 [78] . The two extracellular domains of ICAM-2 have 34% 
homology to the first two amino terminal domains oflCAM-1 [78]. Cell surface ICAM-2 is 
postulated to be a monomeric protein [44, 58]. 
ICAM-2 and Ligand Binding 
The Bz integrins LFA-1 and Mac-1 are the ligands that bind ICAM-2 [20, 32, 78, 83, 84, 
85] . Like human ICAM-1 , ICAM-2 does not contain the calcium binding ROD sequence 
found in most integrin ligands [78]. Mutational analysis of cDNA encoding ICAM-2 revealed 
that the LFA-1 binding site is in domain one [86]. The Mac-1 binding site is also in domain 
one [32]. 
The exact role of ICAM-2 in the inflammatory process has yet to be elucidated. There 
are multiple hypotheses to its role in leukocyte adhesion. One hypothesis is that ICAM-2 on 
vascular endothelium serves as the initial ligand for LFA-1 on neutrophils early on in the 
inflammatory process [11 , 82]. Another hypothesis is that ICAM-2 on unactivated endothelium 
may serve as a ligand for LFA-1 on memory T cells to facilitate their recirculation through 
resting endothelium [82] . Evidence for these assumptions come from the fact that ICAM-2 is 
expressed 10-15 fold higher on unactivated endothelial cells as compared to ICAM-1 [17] and 
the amount of time required for endothelial cells to upregulate their surface expression of 
ICAM-1 (see above) [50]. 
Experiments by de Fougerolles et al. (1991) and Xu et al. (1996) showed that LFA-1 
has a higher affinity and avidity for ICAM-1 than ICAM-2 in activated leukocytes. Antibodies 
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against ICAM-2 do little to inhibit LFA-1 dependent homotypic aggregation of activated 
lymphocytes when ICAM-1 and ICAM-2 are present on the cell surface [45, 82]. Antibodies 
against ICAM-1 and ICAM-2 are needed to further decrease homotypic adhesion, but 
aggregation is still not completely ablated suggesting the presence of a third LFA-1 ligand [45, 
80, 82]. 
ICAM-3 
ICAM-3 is a cell surface protein with a limited distribution and has not been as 
extensively studied as ICAM-1. The CD designation for ICAM-3 is CD50 [87]. Its cellular 
expression is restricted to cells of lymphoid and myeloid origin [88, 89]. Approximately 95% 
of human B and T lymphocytes, 60% of thymocytes, 70-85% of monocytes/macrophages, and 
98% of neutrophils, constitutively express high levels of ICAM-3 [88, 90]. Inflammatory 
mediators do not increase the surface expression of ICAM-3 [88]. 
Endothelial cells do not normally express ICAM-3 [44, 45]. The exception to this 
restricted pattern of expression is in the case of lymphoma and myeloma where more than fifty 
percent of patients exhibit ICAM-3 expression on vascular endothelium [ 44, 45]. The reason 
for tumor-induced expression of ICAM-3 is presently unknown [22]. ICAM-3 has been 
cloned and sequenced in humans, rabbits, dogs, mice, rats and the bovine [44, 54, 91, 92, 93]. 
Its cellular distribution and results of in vitro studies suggest a role for ICAM-3 in the 
inflammatory process. The finding that resting T lymphocytes adhere to other leukocytes 
expressing LFA-1 primarily through ICAM-3 and not ICAM-1 or 2, combined with its high 
expression on these cells implies ICAM-3 has an important role in the initiation of the immune 
response [11, 88]. In vitro studies of T cells with various antigen presenting cells showed 
ICAM-3 to act as a costimulatory molecule in T cells and to aid in stabilizing the T cell-antigen 
presenting cell interaction [90, 94]. 
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ICAM-3 Structure 
The ICAM-3 gene structure has not been determined but preliminary data suggests that 
the overall exon organization and intron sizes are conserved between human ICAM-1 and 
ICAM-3 [44]. Analysis ofICAM-3 cDNA places it in the immunoglobulin superfamily [91, 
93]. Encoded in this 1739 base pair cDNA is a putative signal sequence, five extracellular lg-
like domains, a hydrophobic transmembrane region, and a cytoplasmic domain [91, 92] . There 
are fifteen potential N-linked glycosylation sites in the extracellular domains of ICAM-3 
yielding a native protein of 124 kDa [92, 93]. At the amino acid level there is 52% homology 
between human ICAM-1 and ICAM-3 and 37% homology between ICAM-3 and ICAM-2 
[93]. 
ICAM-3 and Ligand Binding 
The ~2 integrins LFA-1 and CDl ld/CD18 are the ligands that bind ICAM-3 [22, 88, 
91, 95]. Mutational analysis of ICAM-3 cDNA revealed the LFA-1 binding site to be in 
domain one ofICAM-3 [96, 97]. Domains three through five do not contain protein 
recognition sequences that bind LF A-1 but may play a role in the presentation of the binding 
site to LFA-1 [96] . Though domain one of ICAM-1 and ICAM-3 both bind LFA-1, there is 
only 38% homology at the amino acid level between these two molecules [45]. It is domain two 
of ICAM-1 and ICAM-3 that exhibit the highest degree of homology at the amino acid level, 
77% [45]. CD11d/CD18 is constitutively expressed on synovial macrophages and 
preferentially binds domain one of ICAM-3 [22]. Like human ICAM-1 and ICAM-2, ICAM-3 
does not contain the calcium binding RGD sequence found in most integrin ligands [97]. 
In vitro analysis of purified LFA-1 binding to ICAM-1 versus ICAM-3 showed that 
LFA-1 has a greater affinity for ICAM-1 than for ICAM-3 [88] . Functional assays using 
antibodies to ICAM-3 only partially blocked homotypic adhesion of leukocytes in vitro [98]. 
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Antibodies to ICAM-1, ICAM-2, and ICAM-3 were needed to achieve complete blockage of 
cell-cell adherence [98]. 
ICAM-4 
In 1994 work on the Landstein-Weiner (LW) blood group antigens identified a novel 
membrane protein on the surface of red blood cells [99] . Sequence analysis and subsequent 
cloning of this protein showed it was homologous to the intercellular adhesion molecules [99], 
[45]. Further cDNA and peptide sequence studies revealed this protein to contain a signal 
sequence, two extracellular lg-like domains, a transmembrane region, and a short cytoplasmic 
tail [99]. The protein had four potential N-linked glycosylation sites in the two extracellular 
domains [22, 99]. In vitro studies showed it had a molecular weight of 42 kDa [45, 99]. In 
1995 Bailly et al. designated this protein ICAM-4. 
ICAM-4 has roughly 30% homology at the amino acid level to domain one ofICAM-1, 
2, and 3 [99]. At domain two the level of homology drops to 25% [99] . In vitro studies 
showed that purified ICAM-4 is able to bind LFA-1 and Mac-1 [100] however the location of 
the integrin binding site in ICAM-4 has yet to be determined [22]. Analysis of leukocyte 
subpopulations binding to purified ICAM-4 in vitro showed B cells and NK cells had a higher 
affinity for binding ICAM-4 than did monocytes and T cells [100]. To date, expression of 
ICAM-4 has been limited to erythrocytes and erythroid precursors [22]. The function and 
biological properties of ICAM-4 remain unknown [22, 100]. 
ICAM-5 
The newest member in the ICAM family is telencephalin, termed ICAM-5 [101]. 
ICAM-5 is a cell surface neuronal adhesion molecule whose expression is confined to 
telencephalic neurons within the telencephalon of mammals [101, 102]. (The telencephalon 
includes the cerebral neocortex, olfactory cortex, hippocampus, stratium, amygdala, septum, and 
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olfactory bulb [101].) In the course of brain development in mammals ICAM-5 is 
constitutively expressed at birth and remains into adulthood [101]. 
ICAM-5 Structure 
cDNA cloning and sequencing of ICAM-5 place it in the immunogloublin superfamily 
[101, 103]. Peptide analysis ofICAM-5 indicates that it has a putative signal sequence, nine 
extracellular lg-like domains, a transmembrane region, and a cytoplasmic tail [101]. There are 
15 potential N-linked glycosylation sites in ICAM-5 yielding a mature peptide of 130 kDa 
[101]. 
ICAM-5 has been cloned and sequenced in the murine, human, and rabbit [101] . 
Human ICAM-5 has 50%, 38%, 55%, and 32% homology at the amino acid level with ICAM-1, 
-2, -3, and -4 respectively [101]. Interestingly, human ICAM-5 has 85% homology at the 
amino acid level with murine and rabbit ICAM-5 [101]. This value is significantly higher than 
the homology between human and murine ICAM-1 (53%) or ICAM-2 (60%) [53, 84]. 
ICAM-5 and Ligand Binding 
In vitro adhesion assays of purified ICAM-5 showed it is able to bind the B2 integrin 
LFA-1 [102, 103]. Recent studies by Tian et al. (2000) mapped the LFA-1 binding site in 
ICAM-5 to domain one. Interestingly, the in vitro binding of ICAM-5 to cells expressing LFA-
1 did not require the presence of divalent cations, or activation of the cell lines [101]. This is 
highly unusual as the B2 integrins expressed on the cell membrane are normally inactive and 
require the presence of divalent cations and activation of the host cell by stimuli to bind ligand 
[27, 30, 104, 105] (see above). T lymphocytes are able to bind ICAM-5 in vitro and antibodies 
against ICAM-5 are able to block this adhesion [102]. 
The role of ICAM-5 in the generation of an immune response is unknown. Presently 
there is little information available on how lymphocytes interact with neurons of the central 
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nervous system, though this interaction is seen in many pathological conditions (i .e. , viral 
infections, auto immune diseases, ischemia, trauma, among others) [102]. Microglial cells (also 
referred to as brain macrophages) constitutively express LFA-1 [101]. When activated these 
cells change their shape, proliferate, and migrate to damaged neurons and remove dead cells by 
phagocytosis [101]. Expression of ICAM-5 on neurons and LFA-1 on microglia may aid in 
this interaction [101]. The brain is viewed as an immunologically privileged site and the 
discovery of ICAM-5 and ICAM-5/LFA-1 interactions may add insight to how leukocytes 
interact with the central nervous system. 
Conclusion 
Leukocyte adhesion to other immune cells and to cells of the extra cellular matrix is a 
key component in generating an effective immune response. The identification of the molecules 
involved, along with their structure and function, has given great insight at the molecular level to 
the processes and interactions involved in leukocyte adhesion. Armed with this information it is 
now possible to manipulate the immune response with mAbs or recombinant molecules for use 
as immunomodulators during chronic and acute inflammation. 
The intercellular adhesion molecules have been identified as major contributors to 
leukocyte trafficking. The ICAM family presently consists of five members. All are ligands 
for LFA-1. Despite the sequence homologies and redundancy in ligand binding, their patterns 
of expression suggest specialized roles . The identification of ICAMs -1, -2, and -3 with their 
known and proposed functions reemphasizes the important role intercellular adhesion 
molecules play in the immune response. ICAM-1 is the most studied intercellular adhesion 
molecule and among the ICAMs has the highest affinity for LFA-1. 
The success of using mAbs to human ICAM-1 and rhICAM-1 for therapeutic 
interventions has opened the doorway for exploration of this molecule in treating inflammatory 
disorders in economically important livestock species. The cloning and sequencing of bovine 
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ICAM-1 by Lee et al. (1997) creates a new area of exploration in veterinary research. The 
investigation of recombinant bovine ICAM-1 and a bovine ICAM-1 mAb for use as an anti-
inflammatory agent for treating bovine mastitis and other inflammatory conditions in the bovine 
is a novel area that will hopefully lead to new therapies to reduce immunopathology. 
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MATERIALS AND METHODS 
Polymerase Chain Reaction (PCR) 
PCR primers were designed from the published cDNA sequence of bovine ICAM-1 
[72) (GenBank Accession No. U65789) to amplify cDNA segments encoding domains 1 and 2 
( designated B 1 ), or domains 1 through 5 ( designated A6) of the extracellular region of bovine 
ICAM-1. Restriction enzyme sites were added to the ends of each primer to facilitate site 
directed cloning. Primers 1 and 2 encoded Bl. Primers 3 and 4 encoded A6 (Table 1). 
Table 1: Primer Design 
Sequence Direction 
1. 5' - CCAGGTACC-GCCGGAATATCAATACA -3' F" 
2. 5' -CGCGGATCC (TTA)-TGGCAGGACATAGGT-3' Rb 
3. 5' - CCAGGTACC-GCCGGAATATCAATACA -3' F" 
4. 5' -ATTGGATCC (TTA)-CTGGCCGTGGAGCA-3' Rb 
( ) = Translation Stop Codon 
a F= Forward Primer 







Bold nucleotide sequences are bovine specific cDNA sequence. The R (Reverse) primer 
sequence is the complement of the 3' end of the cDNA sequence. 
Each PCR reaction was carried out in a total volume of 50 rnicroliters (µl). 700 pico 
grams (pg) (350 pg/µl) of bovine cDNA from a plasmid encoding the complete bovine ICAM-1 
open reading frame supplied by Lee et al. (1997) served as the template. A single set of primer 
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pairs was added to the reaction mixture from a 10 micromolar (µM) stock to a final 
concentration of 0.2 µM for each primer (1 µ1/primer). dNTPs (Boehringer Mannheim, 
Indianapolis, IN) from a stock of 10 milliMolar (mM) were added to a final concentration of 
0.2 mM (1 µl total dNTPs). Five microliters of 10 X PCR Buffer (100 mMTris-HCl, 15 mM 
MgC12, 500 mM KCl, pH 8.3; Boehringer Mannheim, Indianapolis, IN) was added for a final 
dilution of 1 X along with 1 Unit (U) Taq Polymerase (5U/µl) (Boehringer Mannheim, 
Indianapolis, IN). Sterile distilled water (39.8 µl) was added to bring the reaction volume to 
50 µl (Table 2). 
Table 2: PCR Reactions 
Reagent Stock Concentration Final Concentration Volume 
bovinecDNA 350 pg/µl 700 pg 2.0 µl 
Primer lOµM 0.2µM 1.0 µIX 2 
DNTPs lOmM 0.2mM 1.0 µl 
PCR Buffer lOX lX 5.0 µl 
Taq Polymerase 5 U/µ1 lU 0.2 µl 
Sterile 8i0 39.8 µl 
Total = 50.0 µl 
The PCR parameters were as follows: 30 seconds at 94°C for denaturing, 45 seconds at 
58°C for annealing, and 1 minute at 72°C for extension. A total of 30 cycles was completed 
with an additional extension time of 10 minutes after the last cycle. All PCR reactions were 
done in triplicate and the respective samples pooled. After pooling of the samples, the 
respective cDNAs for the two constructs were cleaned using the Wizard PCR Clean-Up Kit 
(Promega, Madison, WI). A double restriction enzyme digest was performed with 2.4 µg of 
each construct using 5 U of Bam HI and Kpn I (GibcoBRL, Rockville, MD). The digests were 
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incubated at 37° C for 90 minutes. After digestion the individual constructs were cleaned with 
the Wizard PCR Clean-Up Kit. 
The Expression Vector 
The pTrxFus plasmid (Invitrogen, Carlsbad, CA) (based upon pUC18 design) contains: 
a co!El origin of replication, a ~-lactarnase gene for ampicillin resistance as a selection marker, 
a polylinker sequence that includes the restriction sites Barn HI and Kpn I, and a gene sequence 
encoding the enterokinase recognition site for cleavage of the bacterial portion of the 
recombinant peptide [106]. The plasmid uses the PL promoter from bacteriophage A to drive 
expression. Regulation of the promoter for transcription of the recombinant protein is under 
the control of the bacteriophage A cl repressor. 
Expression of the cl repressor is also regulated. The E. coli strain used for 
transformations contains the cl repressor gene under control of the trp promoter (see below). 
The trp repressor and attentuator regulate expression of the cl repressor [106]. When 
transformed cells are grown in tryptophan-free medium, the cl repressor gene is transcribed, 
and the cl repressor protein binds the PL promoter preventing transcription [106, 107]. 
Expression is induced by adding tryptophan to the medium thereby stopping cl repressor 
synthesis [106, 107] and allowing transcription from the PL promoter. 
Ligations 
The pTrxFus expression vector was digested in a 40 µ1 double reaction. Five micro 
grams of the expression vector (lµg/µl) was digested in 20 U each of Barn HI and Kpn I 
(lOU/µl) along with 4.0 µl 10 X REact® 4 (200 rnM Tris-HCI, 50 rnM MgC12, 500 rnM KCl, 
pH 7.4; GibcoBRL), and the addition of 27 µl sterile deionized distilled water brought the 
reaction volume to 40 µl. The reaction was incubated at 37° C for 90 minutes. The Wizard 
PCR Clean-Up Kit was used to remove enzymes and cut nucleotides following digestion. 
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Digestion of the expression vector with two different restriction enzymes resulted in a 
linearized vector yielding non-compatible ends. This alleviated the problem of vector self 
ligation or treating the vector with alkaline phosphatase. Both ICAM truncations contained 
restriction enzyme sites at each end to aid in site directed cloning and maximize the probability 
of obtaining a clone with the proper orientation. The goal was to ligate each construct 
separately into the pTrxFus expression vector down stream and in frame with the sequence 
coding for the expression tag, thioredoxin. 
To produce a construct encoding the first two domains of bovine ICAM-1, the PCR 
product generated from primers 1 and 2 (Bl) was ligated with linearized pTrxFus in the 
presence of 1 U T4 DNA ligase (GibcoBRL, Rockville, MD). The insert to vector molar ratio 
was 2:1. The PCR product derived from primers 3 and 4 (A6) encoding all five extracellular 
domains of bovine ICAM-1 was ligated into pTrxFus in the same manner as above. All 
ligations were incubated at 15.8°C for 12 hours. 
Transformations 
Escherichia coli strain 01724 (Invitrogen) was streaked out on a Luria-Bertani (LB) 
agar plate and placed in a 37° C incubator overnight. A single colony from this plate was used 
to inoculate 50 ml of LB Medium and grown for 16 hours in a 37° C shaking incubator. One 
liter of LB Medium was inoculated with the 50 ml overnight culture and grown at 37° C until the 
optical density (OD) at 550 nm was 0.7. The 1 L culture was split into two cold 500 ml 
centrifuge bottles and incubated on ice for 30 minutes. Cultures were centrifuged at 2000 X g 
for 15 minutes at 4°C and the supernatant decanted. Each pellet was resuspended in 250 ml 
cold sterile distilled water and centrifuged at 2000 X g for 15 minutes at 4°C. Supernatant was 
decanted and 20 ml cold sterile 10% glycerol (diluted in water) was added to each pellet and the 
pellets were transferred to separate cold 50 ml centrifuge tubes . Cells were centrifuged at 4000 
X g for 15 minutes at 4°C and the supernatant decanted. Each pellet was resuspended in 1 ml 
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cold sterile 10% glycerol and pooled into one 50 ml tube and placed on ice. The cell 
suspension was pipetted into 1.5 ml microcentrifuge tubes in 45 µ1 aliquots, quick frozen in a 
dry ice-ethanol bath, and stored at -70°C until ready for use. 
The electrocompetent cells were transformed with 1 µl of each ligation reaction in 
separate tubes. The mixture was added to a Gene Pulser® IE. coli Pulser'M Cuvette (BIO-RAD, 
Hercules, CA). Electroporation was carried out using the BIO-RAD Gene Pulser™ with the 
following parameters: volts= 2.5, resistance (ohms)= 200, and capacitance (micro Faradays) = 
25. After electroporation 800 µ1 of SOC Medium (Invitrogen, Carlsbad, CA) was added to each 
cuvette and the mixtures were quickly transferred to separate 14 ml sterile polystyrene Falcon® 
tubes (Benton Dickinson, Franklin Lakes, NJ). The cultures were placed in a 30° C shaking 
incubator for 1 hour. 
Fifty microliters of transformed cells were plated on RMG-Agar (Invitrogen, Carlsbad, 
CA) plates containing 100 µg/ml ampicillin and incubated at 30° C for 24 hours. Three 
milliliters RM Medium (Invitrogen, Carlsbad, CA) containing 100 µg/ml ampicillin were 
inoculated with a colony containing either construct and grown at 30°C in a shaking incubator 
for 24 hours. DNA plasmid minipreps (Promega, Madison, WI) were done on all cultures 
containing either construct for DNA sequence analysis (Iowa State University DNA 
Sequencing Facility). Cultures containing either truncated ICAM construct were frozen in 20% 
glycerol (in water) at -70°C until further use. As a control for recombinant expression the 
pTrxFus vector without any insert was transformed into the competent cells. 
Small Scale Expression of Soluble Recombinant Bovine ICAM-1 
One ml of RM medium containing 100 µg/ml ampicillin was inoculated with a 
transformed colony containing either construct (B 1 or A6) or the pTrxFus expression vector 
(no insert) and grown overnight in a 30° C shaking incubator. Ten milliliters of Induction 
Medium (Invitrogen, Carlsbad, CA) in a 25 ml flask were inoculated with 500 µl of overnight 
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culture from either construct or control, and grown until the OD550 was 0.7. One ml was 
removed and labeled as time zero. Tryptophan was added to the remaining cultures to a final 
concentration of 100 µg/ml from a 10 mg/ml stock to induce expression. Cultures were placed 
in a 37° C shaking incubator and expression was allowed to proceed for 4 hours. One ml from 
each culture was removed and placed in a microcentrifuge tube on ice at the 1, 2, 3, and 4 hour 
time points respectively. 
Cells from the various time points were pelleted in a microcentrifuge at 20,000 X g for 3 
minutes. Cell pellets were resuspended in 500 µl cold Osmotic Shock Solution #2 (lnvitrogen, 
Carlsbad, CA) and placed on ice. Cells were sonicated using a sonicator equipped with a mico 
tip one at a time with three 10 second bursts then flash frozen in a dry ice-ethanol bath and 
thawed in a 37° C water bath. Three sonication freeze/thaw cycles were completed for each 
sample. After the last freeze/thaw, the cells were pelleted at 20,000 X g for 5 minutes in a 
microcentrifuge. Supematants were transferred to clean microcentrifuge tubes and pellets ( cell 
debris and insoluble matter) were resuspended in 500 µl cold Osmotic Shock Solution #2. 
Large Scale Expression and Affinity Purification 
Fifty milliliters RM-Media containing 100 µg/ml ampicillin were inoculated with a 
loopful of bacteria containing either ICAM construct. Cultures were grown over night in a 
shaking incubator at 30° C. One liter of Induction Medium containing 100 µg/ml ampicillin 
was inoculated with 50 ml of RM-Media containing either construct. The cultures were grown 
in a 30°C shaking incubator until an OD550 of 0.6 and then stimulated with 100 µg/ml 
tryptophan for 4 hours at 37°C to induce expression. 
Cells were harvested by centrifugation at 4000 X g for 15 minutes at 4° C and the pellets 
were resuspended in 20 ml running buffer (100 mM HEPES pH 7.0, 1 mM EDTA, lmM 13-
mercaptoethanol). Cells were disrupted by passing three times through a cold French Pressure 
Cell (American Instrument Co., Savage, MD) at 14,000 lb./in2• The lysate was centrifuged at 
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10,000 X g for 15 minutes at 4° C to pellet cell debris. The supernatant was removed and 
placed in a clean tube. 
The protein in the soluble lysate (supernatant) was quantitated using the Kalckar 
formula [108](amino acid composition at 260 nm and 280 nm). Forty milligrams of soluble 
lysate (2.5 mg/ml) was added to 2 ml equilibrated ThioBond™ Resin (lnvitrogen, Carlsbad, CA) 
for affinity chromatography. The ThioBond Resinr" was equilibrated according to the 
manufacturer's instructions. The resin was washed with 8 ml running buffer and the 
recombinant protein was eluted off the column using running buffer containing increasing 
concentrations of ~-mercaptoethanol (125 mM to 350 mM). 
Inclusion Body Production, Solubilization, and Purification Using Ion Exchange 
Chromatography 
Fifty milliliters RM-Media containing 100 µg/ml ampicillin was inoculated with a 
loopful of bacteria containing either ICAM construct. Cultures were grown over night in a 
shaking incubator at 30° C. One liter oflnduction Medium containing 100 µg/ml ampicillin 
was inoculated with 50 ml of RM-Media containing either construct. The cultures were grown 
in a 30°C shaking incubator until an OD550 of 0.6 was reached and then stimulated with 100 
µg/ml tryptophan for 4 hours at 37° C. 
Cells were harvested by centrifugation at 4,000 X g for 15 minutes and resuspended in 
20 ml HEPES buffer (50 mM HEPES-NaOH pH 7.5, 0.5 M NaCl, 1 mM PMSF, 5 mM DTT 
(dithiothreitol) containing 0.35 mg/ml lysozyme) per liter of cell culture and placed at 20°C for 
30 minutes. Triton X-100 was added to a concentration of 1 % (vol/vol) and the bacteria were 
sonicated, then treated with 200 µl DNase I (10 mg/ml) and placed at 37°C for 1 hour and 
finally, the extract was centrifuged at 30,000 X g for 30 minutes at 4°C. 
The recombinant ICAM-1 was contained in the pelleted inclusion bodies as determined 
by western blot analysis. Pellets were washed twice in phosphate buffered saline (PBS, 0.80% 
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NaCl) containing 1 % Triton X-100 at 30,000 X g for 30 minutes at 4°C and solubilized in 2 ml 
50 mM HEPES-NaOH pH 7.5, 6 M guanidine-HCl, 25 mM DTT and left for 1 hour at 4°C. 
Insoluble material was removed by centrifuging the extract at 100,000 X g for 10 minutes and 
the supernatant was adjusted to 1 mg/ml using 50 mM HEPES-NaOH pH 7.5, 6 M guanidine-
HCl, 25 mM DTT. The solubilized proteins were immediately diluted 1: 10 in cold folding 
buffer (50 mM HEPES pH 7.5, 0.2 M NaCl, 1 mM DTT, IM NDSB256 
(dimethylbenzlammonium propane sulfonate, Cal Biochem, San Diego, CA) vortexed for 30 
seconds, and kept at 4°C for 1 hour. Protein concentration was determined by using the BIO-
RAD (Hercules, CA) Protein Standard Assay, based on the Bradford dye-binding procedure. 
To remove guanidine-HCl the protein solution was dialyzed using snake skin dialysis 
tubing (molecular weight cutoff 10,000) (Pierce, Rockford, IL) against low salt ion exchange 
buffer (20 mM Tris-HCI, 25 mM NaCl, 10 mM ~-mercaptoethanol; pH 8.0) with frequent 
buffer changes. 
Ion Exchange Chromatography 
Partially purified recombinant protein containing bovine ICAM-1 domains 1 through 5 
was obtained by ion exchange chromatography using DEAE-Sephacel (Sigma, St. Louis, MO) 
anion-exchange. Sixty milliliters of preswollen DEAE-Sephacel anion exchanger were poured 
into a 250 ml beaker. One hundred milliliters of filtered, degassed low salt ion exchange buffer 
were added to the beaker. The resin was allowed to settle and the buffer and fines were 
aspirated off. This step was repeated three times. The resin was resuspended in a small volume 
of degassed column buffer and packed into a 25 X 10 cm glass column yielding 35 ml of anion 
exchanger. The column was equilibrated with 10 column volumes (350 ml at 1 ml/min) of 
degassed low salt ion exchange buffer at 4° C. The pre-equilibrated sample (400 ml, 
220 µg/ml) (see above) was loaded onto the column at a flow rate of 1 ml/min. The column was 
washed with 10 column volumes of degassed low salt ion exchange buffer until base line levels 
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of protein were detected using UV spectrometry at 280 nm. Bound proteins were eluted using a 
salt gradient. The gradient was generated by mixing the low salt ion exchange buffer with a 
degassed high salt buffer (20 mM Tris-HCl, 500 mM NaCl, 10 mM B-mercaptoethanol; pH 
8.0). Four hundred milliliters of each buffer were used for the gradient. Fractions were 
collected in 5 ml aliquots. 
Electrophoresis 
Electrophoresis of all protein samples was run on precast 12% and 14% SDS-PAGE 
(sodium dodecyl sulfate-polyacrylamide gel electrophoresis) Tris-Glycine mini gels (Novex, 
San Diego California) based on the Laemmli system [109]. Samples were prepared by adding 
equal volumes of sample and 2 X NuPAGE SDS Sample Buffer pH 8.5 (Novex) supplemented 
with 5 mM B-mercaptoethanol and heated at 100° C for 4 minutes. The XCell II™ Blot Module 
(Novex) slab gel apparatus was used with a BIO-RAD Power Pac 200 power supply. Samples 
were electrophoresed for 90 minutes at 125 volts and either silver or Commassie stained, or 
prepared for western blot transfer. 
Coomassie Blue Stain 
A coomassie blue (Coomassie Brilliant Blue R-250, Boehringer Mannheim) working 
solution (12.5% wt/vol Coomassie Blue Powder, 25% reagent grade methanol, 10% reagent 
grade acetic acid; Mallinckrodt, Paris, Kentucky) was filtered through a 0.45 µm membrane 
(CORNING® Costar, Coming, NY). Destaining solutions of 50% methanol, 10% acetic acid 
(Destain I) and 5% methanol, 7% acetic acid (Destain II) were used to remove unbound 
Coomassie. Briefly, after samples were electrophoresed gels were stained in Commassie 
Working solution for 2 hours, placed in Destain I for 1 hour, and finally placed in Destain II 
for up to 24 hours. 
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Silver Stain 
Following electrophoresis of samples (see above) gels were stained with the Silver Stain 
Plus Kit (BIO-RAD) to detect proteins. Briefly, gels were fixed for 20 minutes in Fixative 
Enhancer Solution (200 ml reagent grade methanol, 40 ml reagent grade acetic acid, 40 ml 
Fixative Enhancer Concentrate (BIO-RAD), 120 ml sterile deionized distilled water), washed 
twice for 10 minutes with deionized distilled water, and stained for 15 minutes in Staining and 
Developing Solution (5 ml Silver Complex, 5 ml Reduction Moderator Solution, 5 ml Image 
Development Reagent, 50 ml Development Accelerator Solution; BIO-RAD). The staining 
procedure was stopped after 15 minutes by placing the gels in 5 % acetic acid in water. 
Western Blotting 
Following electrophoresis of samples on 12% SDS-PAGE gels, proteins were 
transferred to 0.2 µm nitrocellulose (Novex, San Diego, CA). Protein transfer was carried out 
using the XCell II™ Blot Module powered by the BIO-RAD Power Pac 200. Eight hundred 
milliliters cold transfer buffer (700 mM Glycine, 25 mM Tris; pH 7.4) were added to the 
module and elution of the proteins from the gel was allowed to proceed for 75 minutes at 20 
volts. 
Western blotting to detect recombinant protein was carried out using SuperSignal® 
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). After transfer, the nitrocellulose 
membranes were washed in 15 ml PBS (0.8 % NaCl) for 5 minutes, incubated in 50 ml azide-
hydrogen peroxide (5 ml 30% Ri02, 0.05 g NaN3, 45 ml PBS) for 5 minutes and rewashed for 
5 minutes in 15 ml PBS. To block non-specific sites, membranes were incubated overnight at 
4°C in 25 ml SuperBlock® blocking buffer (Pierce, Rockford, IL) supplemented with 0.05% 
(vol/vol) Tween-20 (Sigma, St. Louis, MO). Blocked membranes were incubated at room 
temperature for 1 hour with an Anti-Thioredoxin"' IgG monoclonal antibody (lnvitrogen, 
Carlsbad, CA) diluted 1:8,000 in 12 ml SuperBlock® blocking buffer supplemented with 
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0.05 % Tween-20. Membranes were washed 5 times (10 minutes/wash) with 15 ml wash 
buffer (PBS supplemented with 0.05 %Tween-20). After the last wash, membranes were 
incubated for 1 hour in 12 ml goat-anti mouse IgG horseradish peroxidase (HRP)-conjugated 
secondary antibody diluted 1:50,000 in SuperBlock®blocking buffer supplemented with 0.05 % 
Tween-20. Membranes were washed again 5 times for 10 minutes with 15 ml Wash Buffer and 
after the last wash were incubated for 15 minutes in 24 ml SuperSignal® Substrate Working 
Solution (12 ml Luminol/Enhancer Solution, 12 ml Stable Peroxide Solution) (Pierce, 
Rockford, IL). Blots were removed from the Working Solution, drained, and enclosed in Saran 
Wrap™. Wrapped membranes were placed in a Kodak BioMax™ Cassette (Kodak, Rochester, 
NY) with intensifying screen and Kodak Bio-Max™MS Film was applied on top for forty-five 
seconds. Films were developed using a Kodak X-OMAT M35 Processor (Kodak). 
Antibody Production 
The immuogen was prepared by pooling fractions eluted from the ThioBond Resin™ 
(Invitrogen) containing rbICAM-1 and contaminating proteins and dialyzed in snake skin 
dialysis tubing (10,000 molecular weight cutoff; Promega) at 4° C against PBS (0.83% NaCl) 
with frequent buffer changes. The dialyzed sample was concentrated using a Centricon Plus-80 
5,000 molecular weight cut-off centrifugal filter device (Millipore, Bedford, MA) and diluted to 
1 µg/µl. 
Four 5 month old female BALB/c mice were immunized with the impure antigen. Each 
mouse was immunized with 50 µg antigen (1 µg/µl), 50 µl PBS (0.83% NaCl), and 100 µl 
Freund's Complete Adjuvant (FCA) intraperitoneally (IP). 
Mice were boosted twice IP at two week intervals, first with 50 µg antigen (1 µg/µl), 
50 µl PBS (0.83% NaCl), 100 µl Freund's Incomplete Adjuvant (FIA), and the second time 
with 25 µg antigen (1 µg/µl), and 75 µl FIA. One week after the second boost, mice were bled 
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via cardiac puncture and tested by Enzyme Linked Immunosorbent Assay (ELISA) (see below) 
for antibody production to rbICAM-1 antigen. 
The mouse that gave the highest antibody titer was selected for further immunization 
and hyperimmunized with 25 µg antigen (1 µg/µl), 75 µl PBS (0.83% NaCl) intravenously (IV) 
and 25 mg antigen 75 ml PBS (0.83% NaCl) IP two days after cardiac bleeding. 
This mouse was selected for fusion, and three days after the last immunization was euthanized 
with a lethal does of CO2 and its splenic lymphocytes fused with SP2/0 mouse myeloma cells 
of BALB/c origin. The resulting hybridoma cell supematants were screened via ELISA for 
antibodies reacting to antigen. (Mice for antibody production were cared for and immunized by 
laboratory personnel at the National Veterinary Service Laboratory, Ames, Iowa). 
Enzyme Linked Immunosorbent Assay (ELISA) 
ELISAs were performed on serum samples from cardiac puncture and hybridoma cell 
supematants in triplicate to determine antibody titers. To detect antibodies to the antigen, 
specifically rbICAM-1, 96-well ELISA plates (Immulon® 1, Dynatech Laboratories Inc., 
Chantilly,VA) were coated with either 100 µ1/well (10 µg/ml) of the impure antigen, pure 
recombinant thioredoxin, or recombinant bovine IL-18 and incubated at 37° C overnight. 
Peripheral wells received Coating Buffer (0.05 M N~CO/NaHCO3; pH 9.6) (Sigma) only. 
After incubation plates were washed 4 times (4 minutes each wash) with wash buffer (PBS-
0.83% NaCl, supplemented with 0.01 % vol/vol Tween-20 Sigma). 
One hundred microliters of serially diluted mouse serum (1:125 to 1:78,000) in wash 
buffer was added to the pre-coated microtiter plate wells and incubated for 2 hours at 37° C. 
The plates were washed as above to remove unbound antibodies. One hundred microliters of a 
1:2,500 dilution of horseradish peroxidase sheep anti-mouse whole immunoglobulin 
(Amersharn Life Science Inc., Arlington Heights, IL) was added to all wells and the plate was 
incubated at 37°C for 30 minutes and washed as above. K-Blue Substrate (Neogen, Lexington, 
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KY) was added to each well (150 µI/well) for color development. The absorbance of each well 
was read at an OD650 in a microplate reader (Molecular Devices Corp. , Menlo Park, CA) and 
cells from the mouse with the highest OD readings selected for hyperimmunization and fusion . 
Subsequently the hybridoma cell supematants were assayed as above. 
Immunofluorescence Analysis by Flow Cytometry to Detect Mononuclear Cell Binding 
ofrbICAM-1 
Preparation of Recombinant Protein 
The antigen used for mice immunizations was also used to detect in vitro biological 
activity of the rbICAM-1 mixture via flow cytometry. Briefly, antigen was dialyzed at room 
temperature for two hours against bicarbonate buffer (17.3 g/L NaHCO3, 8.6 g/L N3.iCO3) with 
frequent buffer changes in a Slide-A-Lyzer lOK dialysis cassette (Pierce). Dialyzed antigen 
was calculated as above (Kalckar method) to be 0.1 mg/ml. Fluorescein isothiocyonate (FITC) 
(Molecular Probes Inc., Eugene, OR) was prepared by diluting in anhydrous dimethyl sulfoxide 
(DMSO) (Aldrich, Milwaukee, WI) to 1 mg/ml in a 100 ml beaker. Forty-five microliters FITC 
solution was added to 1 ml recombinant protein mixture (antigen), mixed and incubated in the 
dark at room temperature for three hours. FITC conjugate was then dialyzed using a Slide-A-
Lyzer cassette in PBS (0.83% NaCl) for two hours at room temperature to remove 
unconjugated reagents. 
Bovine Blood Collection 
Cattle from the Holstein dairy herd at the National Animal Disease Center, Ames Iowa 
were either normal or carried the homozygous recessive BLAD allele (see literature review) 
determined via PCR and pedigree analysis . Whole blood was collected in EDTA Vacutainer® 
glass tubes (Becton Dickinson, Franklin Lakes, NJ) via jugular vein puncture from each animal. 
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Fluorescent Activated Cell Sorting Analysis (FACScan) 
Conjugated protein (truncated A6 containing the first three and half extracellular 
domains of bovine ICAM-1) was diluted to 1 µg/ml in PBS (0.83% NaCl) and 100 µl (0.1 µg) 
added to two wells of a 96-well U-Bottom plate (COSTAR®, Cambridge, MA). One hundred 
microliters whole blood from each animal was separately added to each well and incubated at 
room temperature for 15 minutes in the dark. The plate was spun at 400 X g for two minutes at 
room temperature. The whole blood was lysed with 200 µl sterile deionized distilled water and 
restored with 20 µl of 10 X NaCl (8.3% NaCl) and lysed with water again . The cells were 
resuspended in 200 µl PBS (0.83% NaCl) supplemented with 0.04% NaN3 and analyzed in a 
FACScan® Flow Cytometer (Becton Dickinson, San Jose, CA) using the software program 
CELLQuest™ (version 3.lf; Becton Dickinson). Mononuclear cells from each animal were 
determined by light scatter characteristics (forward and side scatter), and only these fractions 




PCR amplification of primers 1 and 2 gave an expected amplified PCR product of 589 
base pairs (bp) (based on primer design) encoding the first two domains of bovine ICAM-1 
(Bl). Bl included the last amino acid of the signal sequence, the first two immunoglobulin-like 
domains, and the first three amino acids of domain 3. Primers 3 and 4 gave an expected 
amplified PCR product of 1375 bp (based on primer design) encoding all five extracellular 
domains of bovine ICAM-1 (A6). The second construct (A6) included the last amino acid of 
the signal sequence and all five extracellular immunogloublin-like domains except for the last 
amino acid in domain 5, asparagine. 
The PCR products included additional amino acids along with the extracellular domains 
as the primers were designed by comparing the human and bovine ICAM-1 cDNA sequences, 
and followed primers designed by Martin et al. (1993) who successfully expressed biologically 
active human ICAM-1 in E. coli [110]. Matching the bovine DNA sequence to the human 
yielded nucleotides that coded for amino acids found in the signal sequence of the bovine or an 
additional amino acid from another domain, thus they were included. 
Both PCR reactions yielded the correct size products based on primer design. Each 
PCR reaction was done in triplicate and pooled to yield enough product for further applications. 
Restriction sites were added to the ends of each primer to aid in directional cloning into 
pTrxFus that contained a multiple cloning site including the restriction sites Barn HI and Kpn I. 
Ligations/Transformations 
After ligations and subsequent transformations pTrxFus containing the ICAM-1 
derivatives was isolated. DNA sequence analysis of both constructs was performed to verify 
that inserts were ligated down stream and in frame with the E. coli expression tag, thioredoxin. 
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Sequencing revealed that one A6 construct had a stop mutation generated during PCR. This 
construct encoded for only the first three and a half domains of bovine ICAM-1, unlike the 
remaining A6 constructs that properly encoded all five extracellular domains. The truncated 
construct of A6 was used for recombinant bovine ICAM-1 antibody production, and testing of 
biological activity in vitro because it had already been produced in abundance, and contained the 
extracellular domains which are important in binding the ~2 integrins (i.e., domains one through 
three). 
Small Scale Expression of Soluble Recombinant Bovine ICAM-1 
To test for expression of recombinant bovine ICAM-1, 10 ml of culture representing 
transformants containing Bl or the shortened A6 construct (encoding domains 1-3.5), and as a 
negative control, pTrxFus with out any insert. Expression was induced (when cultures reached 
an OD550 of 0.7) with the addition of tryptophan, and one hour time points were taken up to 4 
hours post induction. SDS-PAGE analysis of the B 1 expression products revealed the 
predicted fusion peptide of 34.4 kDa for the first two domains of bovine ICAM-1 fused C-
terminus to E. coli thioredoxin. The negative control pTrxFus without any insert produced an 
expected protein at 16 kDa, lacking the 34.4 kDa recombinant protein band (Figure 1). 
SDS-PAGE analysis of the truncated A6 construct revealed the predicted molecular 
weight of 56 kDa for the first three and a half domains of bovine ICAM-1 fused C-terminus to 
E. coli thioredoxin. The negative control pTrxFus without insert once again produced the 
expected protein band at 16 kDa and lacked the 56kDa recombinant protein band. However, 
comparing the densities of the two cell fractions on SDS-PAGE (insoluble pellet and soluble 









Figure 1. Coomassie stained gel of (Bl) recombinant bovine ICAM-1 domains 1 and 2. Lanes 
1-5 are samples of the insoluble pellet from lysed cells at 0, 1, 2, 3, and 4 hour post induction. 
(Induction with tryptophan was at O hour) Lanes 6-10 are the same time points for the soluble 
protein supernatant. Arrows in lanes 4, 5, 8-10 denote protein bands of the expected molecular 
weight for the recombinant protein, 34.4 kDa. Lane 11 is the negative control, pTrxFus without 
any insert. 16 kDa band (arrow) is the expected size of thioredoxin in this system. (Molecular 
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Figure 2. Coomassie stained gel of truncated A6 construct. Truncated constructed was 
identified after expression and encoded the first three and a half domains of bovine ICAM-1. 
Lanes 1-5 are insoluble pellet from lysed cells at 0, 1, 2, 3, and 4 hour post induction. 
(Induction with tryptophan was O hour.) Lanes 6-9 are the time points 1-4 hours post induction 
for the soluble protein supernatant. Arrows in lanes 4, 5, 8, 9 denote protein bands of the 
expected molecular weight of the A6 truncation, 56 kDa. Lanes 10 and 11 are negative control, 
pTrxFus without any insert. 16kDa band (arrow) is the expected molecular weight for 
thioredoxin in this system. (Molecular weight positions are shown on the left.) 
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Large Scale Expression and Affinity Purification 
Since the small scale expression was successful, the expression of the truncated A6 
construct coding for the first three and a half extracellular domains of bovine ICAM-1 was 
scaled up to recover more recombinant protein. One liter of Induction Medium inoculated with 
50 ml of an overnight culture of the truncated A6 construct was induced at an 0D550 of 0.6 with 
tryptophan for 4 hours at 37° C. The pelleted bacteria were resuspended, lysed by french 
pressing, centrifuged, and the cell lysate applied to an equilibrated ThioBond™ column for 
affinity purification. This column was provided as a component in the Thiofusion™ Expression 
System as thioredoxin has an affinity for the arsenic in the resin. Application of the soluble cell 
lysate to the ThioBond™ resin and subsequent elution with running buffer containing increasing 
amounts of ~-mercaptoethanol yielded little recombinant protein in the eluents and contained 
contaminating proteins (Figure 3). 
Most of the rbICAM-1 was located in the insoluble cell debris as detected by western 
analysis. Protein eluted off the ThioBondTM columns containing rbICAM-1 was less than 1 % of 
the total cellular protein. To increase soluble protein yields, many liters of the construct were 
expressed and run on multiple columns with the resulting eluents pooled and concentrated. 
This led to significant aggregation and an even further loss of protein. 
As soluble protein yields were extremely low, the inclusion bodies were subsequently 
solubilized and rbICAM-1 was obtained in a semi-pure extract as detected by silver staining and 
western analysis. 
Inclusion Body Production, Solubilization, and Purification Using Ion Exchange 
Chromatography 
An A6 construct properly encoding all five extracellular immunoglobulin-like domains 
of bovine ICAM-1 was used for inclusion body expression, solubilization, and purification via 









Figure 3. Coomassie stain of concentrated eluent off ThioBond™ columns. Fraction shown is 
from a pooled large scale expressions of truncated A6 construct (arrow) used for antibody 
production and flow cytometry. Recombinant bovine ICAM-1 was identified in the soluble 
fraction via western blot analysis (not pictured). (Molecular weight positions are shown on the 
left.) 
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inclusion bodies greatly improved the overall yields of recombinant protein. The A6 construct 
was expressed as above and the detection of recombinant protein in the inclusion bodies was 
verified by western analysis. Recombinant protein yields were in excess of 10% of the total 
cellular protein as determined by the Kalckar method. 
Solubilization of the inclusion bodies in 6 M guanidine-HCI yielded denatured protein. 
Diluting the recombinant protein to 1 mg/ml followed by the quick addition of 1 M NDSB 
eliminated aggregation and improved overall recombinant protein yields. There was no further 
aggregation of protein following removal of the guanidine and NDSB by dialysis. 
The isoelectric point (pl) of recombinant bovine ICAM-1 containing all five extracellular 
domains fused to thioredoxin was calculated to be 5.36 using the software program 
Mac Vector™ (version 5.0; Kodak) . Knowing the pl of the recombinant protein allowed for the 
determination of which type of ion exchanger to use and the pH to carry out ion exchange 
chromatography. 
Eighty-eight milligrams (400 ml, 220µg/ml) of equilibrated recombinant protein were 
loaded on to the DEAE-Sephacel anion exchange column and the various fractions from the 
washes and salt gradient were analyzed. The elution profile of the 5 ml aliquot fractions was 
plotted as measured by OD280 spectrophotometer readings (Beckman Du® -64 ; Beckman 
Instruments, Fullerton, CA) and peaks were identified and run on SDS-PAGE gels for silver 
staining and western blot analysis (Figures 4 and 5). 
Western blot analysis using the Anti-Thioredoxin™ monoclonal antibody identified the 
predicted recombinant protein of 63 kDa, the correct size for the five extracellular domains of 
ICAM-1 fused to thioredoxin (Figure 5A). Silver staining showed that the recombinant protein 
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Figure 4. The elution profile of recombinant bovine ICAM-1 (A6, containing all five 
extracellular domains) from the DEAE Sephacel column. Elution of the solubilized inclusion 
bodies was with a linear gradient of 0.025 - 0.5M NaCl. The gradient was started at fraction 94 
and 5 ml fractions were collected. The (*) plot shows the elution of total protein from the 
column. The (X) plot shows the elution of thioredoxin tagged ICAM-1 as determined by 
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Figure 5. 12% SDS-PAGE gels of specified fractions of ICAM-1 (A6, domains 1-5) from the DEAE Sephacel Column. 
Western blots (A) and silver stained gel (B) for fractions 110-180. Western blots, using an anti-thioredoxin monoclonal 
antibody, were used to locate fractions containing peak recombinant bovine ICAM/fhioredoxin protein from the column 
fractions (A). Silver staining showed relative purity of the peak ICAM fractions (B). 
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Antibody Production and ELISAs 
ELISAs indicated that mice immunized with the truncated construct of A6 produced 
antibodies to rbICAM-1. Since the antigen preparation was impure and thioredoxin was still 
fused to rbICAM-1 , ELISA wells were also coated with purified thioredoxin. This allowed for 
the identification and selection of mice that reacted with higher antibody titers to rbICAM-1 
than to the thioredoxin portion of the protein. A mouse was identified that had the highest 
antibody titers to rbICAM-1 among the three remaining mice (one mouse died nine days post 
immunization) and this mouse was selected for hyperimmunization and fusion . The resulting 
hybridoma supematants were also screened as above as there was not a pure form of rbICAM-1 
available. The screening of the hybridoma supematants yielded some strong reacting cultures, 
but due to impure antigen, further screening had to be postponed. 
The three remaining mice reacted weakly to recombinant bovine IL-18 produced in our 
lab based on the obtained OD650 plate readings. This was expected, as the mice were not given 
this antigen. This was done to serve as a negative control. 
Fluorescent Activated Cell Sorting Analysis (FA CScan) 
The flow cytometry data revealed that the rbICAM-1 contained some biological activity 
as measured by immunofluorescence. The cattle selected as cell donors for in vitro analysis 
were either homozygous recessive for BLAD, or normal homozygous. The genetic make up of 
the BLAD animal was verified via PCR and pedigree analysis. The genetic make up of the 
homozygous normal animal was verified via PCR and pedigree analysis. Leukocytes from 
BLAD animals are deficient in the CD 18 subunit of the ~2 integrins, an ICAM-1 ligand. Their 
white blood cells are unable to adhere to ICAM-1. Leukocytes from normal homozygous 
animals are able to bind ICAM-1 efficiently. The availability of a BLAD animal allowed us to 
test the biological activity ofrbICAM-1 and assess its usefulness. 
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There was less binding ofrbICAM-1 to cells from the BLAD animal as opposed to 
cells from the normal bovine. The histogram in Figure 6 shows that 28% of the normal 
animal's mononuclear cells bound rbICAM-1 compared to 4.81 % of the BLAD animal's 
mononuclear cells. 
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Figure 6. The percent binding of rbICAM-1 (A6 truncated) to gated mononuclear cells from whole blood. (A) FACScan 
histogram of cells from a cow that was homozygous normal for CD18 expression. 0.1 µg semi-pure recombinant protein 
bound 29% of gated mononuclear cells. (B) Histogram of cells from an animal that was homozygous for the BLAD allele. 
0.1 µg of recombinant protein bound 4.81 % of gated BLAD mononuclear cells. 
49 
DISCUSSION 
The objective of the work presented in this thesis was to express soluble heterologous 
fusion proteins of recombinant bovine ICAM-1 in E. coli as part of an overall strategy for the 
isolation and purification of this adhesion molecule, and to produce a monoclonal antibody 
against bovine ICAM-1. The purified recombinant protein was to be investigated in future 
experiments for its potential as an anti-inflammatory agent in treating bovine mastitis and other 
inflammatory conditions in the bovine. In attempting to achieve this objective, the usual caveats 
in expressing mammalian genes in E. coli were encountered. Specifically, the formation of 
rnisfolded, inactive recombinant proteins in the cytoplasm, termed inclusion bodies. Inclusion 
body formation is not uncommon when expressing heterologous genes in E. coli [106, 111, 
112]. 
Inclusion bodies representing protein deposits were first identified in the blood cells of 
patients with abnormal hemoglobins, and subsequently in E. coli by Prouty and Goldberg 
(1972), as damaged native proteins [111, 113] . The exact mechanism and reason why foreign 
proteins expressed in E. coli are usually found in inclusion bodies has not been elucidated. 
Initially recombinant proteins formed in inclusion bodies were attributed to incorrectly 
transcribed or translated sequences, however the recovery of active proteins from inclusion 
bodies demonstrates that the problem is one of conformation, not of sequence or modification 
[111]. 
It is also not simply a response to foreign protein as native E. coli cytoplasmic proteins 
synthesized to high levels using recombinant DNA techniques also accumulate in inclusion 
bodies [112, 113]. Recombinant protein length and cysteine residue content (leading to 
disulfide crosslinks) are thought to play a role in the solubility of heterologous proteins 
synthesized in E. coli [106, 111]. However, small homologous and heterologous proteins 
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lacking native disulfide bonds can also accumulate in inclusion bodies, thus inclusion body 
formation cannot solely be attributed to incorrect disulfide formation [111]. 
Current recombinant DNA technology utilizes the use of "tags" or fusion proteins 
(linking the foreign gene to an already known gene that is expressed well in E. coli) to assist in 
heterologous expression and easy purification. The "tag" allows for one-step purification of 
recombinant proteins using affinity chromatography. The maltose binding protein (malE) and 
glutathione-S-transferase (GST) are two popular systems used for heterologous expression of 
proteins in E. coli [106]. For the maltose binding protein, an amylose resin column, which has 
an affinity for the maltose protein portion of the recombinant protein, is utilized for easy 
purification. However fusion proteins expressed in these systems can also lead to inclusion 
body formation [ 106]. 
To alleviate the problems associated with the expression of foreign proteins in E. coli 
(e.g., inclusion body formation); La Vallie et al (1993) devised an E.coli thioredoxin gene 
fusion system for expression of heterologous proteins. Thioredoxin was originally found in E. 
coli as a hydrogen donor for ribonuclease reductase, and has since been found in yeast, plants, 
and mammals [114]. The unique features of this expression system are as follows: E. coli 
thioredoxin is highly soluble, heat stable, and localizes between the inner and outer membranes 
(the adhesion zones) of the cell wall [106]. 
La Vallie reasoned that heterologous proteins attached to E. coli thioredoxin would 
exhibit the same properties as native thioredoxin (i.e., high solubility and thermal stability). 
Also the cellular location of thioredoxin would make it easier to obtain recombinant protein, as 
protein from the adhesion zones can be quantitatively released to the exterior of the cell by 
osmotic shock or freeze/thaw treatments [106]. 
Indeed, La Vallie did show that fusion proteins fo1merl y expressed as insoluble 
inclusion bodies were made soluble in his system. Recombinant human interleukin-2, (IL-2), 
interleukin-4 (IL-4), and interleukin-6 (IL-6) were expressed in insoluble inclusion bodies [115, 
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116, 117], but were expressed as soluble fusions with biological activity in the thioredoxin 
system [106]. La Vallie also showed the same success for some murine cytokines that were 
previously expressed as insoluble inclusion bodies, but were made soluble in the thioredoxin 
system [106]. The usual problems associated with heterologous protein expression in E. coli 
made this expression system (patented to Invitrogen) an attractive one for attempting to express 
and obtain recombinant soluble bovine ICAM-1. 
Previous studies from Martin et al. (1993) and Staunton et al. (1990) were referenced 
and used as a guide in designing bovine ICAM-1 primers and aided in deciding which domains 
of the bovine homologue needed to be expressed. Martin et al. expressed human ICAM-1 in 
an E. coli system and obtained biologically active recombinant protein for use in in vitro assays 
after solubilizing the inclusion bodies and refolding the recombinant protein. Obtaining 
recombinant protein with the correct tertiary structure was not easy as Martin had to use a 
myriad of refolding protocols to empirically determine the best refolding conditions [110] . 
Staunton et al. identified the important domains needed in human ICAM-1 for ligand binding to 
the !32 integrins by deleting the various extracellular domains by oligonucleotide mutagenesis. 
The work of Staunton showed that the cytoplasmic domain and domains 3-5 of human ICAM-1 
were not needed to bind LFA-1 in vitro [60]. Amplifying all five extracellular domains of 
bovine ICAM-1 (A6) and domains 1 and 2 (Bl) would test if the same were true in the bovine. 
The use of the ThioFusion'M Expression System (lnvitrogen) did not alleviate the 
common problem of inclusion body formation in expressing recombinant bovine ICAM-1. 
Although the expression system did express a great deal of recombinant protein, greater than 
90% of it was in the insoluble inclusion bodies. The ThioBond™ Resin, which contains arsenic, 
has an affinity tag for E. coli thioredoxin. Since very little recombinant protein was in the 
soluble fraction (which was subsequently applied to the column) it was difficult to assess the 
effectiveness of the affinity column. 
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At first, the recombinant bovine ICAM-1 protein from inclusion bodies was not 
solubilized, as it was easier to pool and concentrate the small amount of recombinant protein 
located in the soluble fraction and forego the difficulties of empirically determining a folding 
protocol (without any guarantee of success). However, pooling and concentrating the soluble 
fractions led to precipitation of the recombinant protein. 
I had some success in using the pooled sample obtained from the small quantities found 
in the soluble fraction as this sample was used for an in vitro assay to detect the biological 
activity ofrecombinant bovine ICAM-1. The results obtained from flow cytometric analysis are 
encouraging as there was differential binding between an animal normal for ~2 integrin 
expression, and one with a defective allelic form, lacking the CD18 moiety of the integrin. 
Since the truncated clone of A6 (encoding bovine ICAM-1 domains 1-3.5) was used for this 
assay, these results help suggest that domains 1-3.5 of bovine ICAM-1 are important in ligand 
binding. 
It is important to note that the E. coli thioredoxin tag was still attached to the 
recombinant protein during this assay. The results may have been more significant if the 
enterokinase cleavage site was utilized. However this was not practical, as there was never 
enough soluble protein to work with for enterokinase cleavage and have enough left over for in 
vitro assays. 
The truncated A6 (was utilized for in vitro assays and antibody production, because it 
was already mass-produced and contained the putative binding domains of the ~2 integrins in 
the bovine). It was probably in monomeric form. This is because the reducing environment of 
the E. coli cytoplasm would likely not allow for disulfide bond formation [106, 111]. However, 
disulfide bonds may form in the periplasmic space of the cell membrane or may spontaneously 
form after cell lysis and contact with the air [111, 112]. As there was no formal refolding 
protocol applied to the recombinant sample, it is most probable that monomeric recombinant 
bovine ICAM-1 bound the mononuclear cells in the flow cytometry assay. This truncated 
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construct of A6 also contained the ROD amino acid sequence typical of integrin ligands and 
found in bovine ICAM-1 in domain 1 [60, 72]. This may have played a role in binding of the 
recombinant protein. 
The observation that monomeric bovine ICAM-1 appeared to bind ligand in vitro, 
parallels experiments by Miller et al. (1995) and Reilly et al. (1995). They found that 
monomeric human ICAM-1 was able to bind the B2 integrin LFA-1 , but not at the same levels 
exhibited by dimeric human ICAM-1. 
Since so much time was invested in working with the soluble portion of the recombinant 
protein, pure recombinant bovine ICAM-1 was not obtained. This hampered attempts to obtain 
a mouse mAb against recombinant bovine ICAM-1, as impure protein was used as an 
imrnunogen, and to isolate a clone specific for bovine ICAM-1 , pure protein was needed to 
screen the available clones. 
It may have been more practical to solubilize the recombinant protein contained in the 
inclusion bodies at the beginning of this experiment. The current literature on protein 
expression suggests that inclusion body formation seems to be the 'norm', not the exception. 
When the inclusion bodies containing recombinant bovine ICAM-1 were finally solubilized, 
there was a great amount of recombinant protein present as detected by Western blot analysis. 
Silver staining of the solubilized inclusion bodies showed that they contained fewer 
contaminants than the soluble extracts. The time spent on the soluble portion could have been 
more wisely allocated in attempting to refold the recombinant protein to its proper tertiary 
structure. 
Using an eukaryotic expression system may have alleviated the solubility problems 
encountered with the Thiofusion™ Expression system (lnvitrogen). The work by Martin et al. 
on human ICAM-1 demonstrated that glycosylation is not needed to obtain biologically active 
recombinant human ICAM-1 [110]. Though the ICAMs are heavily glycosylated, especially 
bovine ICAM-1 with 13 potential N-linked glycosylation sites [72], glycosylation of the 
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ICAMs is thought to play a major role in the solubility of the molecules and transport to the cell 
surface and not a major role in ligand binding [63]. This may not be the case in ICAM binding 
to the ~2 integrin, Mac-1 [46]. In the current literature, there was not any mention of solubility 
problems in expressing recombinant ICAMs in eukaryotic systems. These expression systems 
are more tedious than the prokaryotic expression systems. 
After solubilizing recombinant bovine ICAM-1, there is now an abundant supply of 
protein to proceed with in vitro assays. Future studies should include cleaving off the 
thioredoxin tag and reapplying the cleaved thioredoxin tag along with recombinant bovine 
ICAM-1 to the anion exchange column as a means for further purification. As the solubilized 
inclusion bodies contained a great deal of recombinant protein, it was not pure upon coming off 
the ion exchange column. Removing the thioredoxin tag (16 kDa) would shift the pl of the 
recombinant protein allowing it to be eluted off the ion exchange column in a different fraction 
from the tag. The contaminating proteins would have the same pl as the first ion exchange run, 
and elute off the column at the same salt concentration as the first run. This would be an 
effective scheme to enrich the recombinant protein and remove the remaining contaminants. 
Various refolding protocols can be utilized to try and renature the recombinant protein. 
The in vitro binding assay with leukocytes from a normal and BLAD animal can be used to test 
for biological activity with results interpreted using a flow cytometer. The correctly folded 
recombinant protein can be used to immunize mice or screen the current frozen hybridoma 
supematants. Obtaining a mAb to bovine ICAM-1 is an important step forward in elucidating 
its role in inflammation, as currently there are no ICAM-1 antibodies that cross-react with the 
bovine [118]. 
With an ample supply of correctly folded recombinant protein, or a bovine ICAM-1 
mAb, there are numerous in vitro blocking assays that can be done to elucidate the role of 
ICAM-1 in bovine inflammatory diseases. If the success of human studies with recombinant 
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human ICAM-1 and a subsequent mAb against it are any indication, there will be many uses for 
the bovine equivalent. 
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GENERAL CONCLUSIONS 
The intercellular adhesion molecules are important proteins of the immune system. 
Though they may bind the same ligands, their patterns of expression suggest specialized roles 
[98]. Of the three identified with respect to leukocyte trafficking (ICAM-1, -2, and-3), ICAM-
1 is perhaps the most important as it exhibits the strictest regulation of expression and has the 
highest affinity for one of the ICAM ligands, the ~2 integrin, LFA-1 [98, 119]. 
Expressing recombinant bovine ICAM-1 in a prokaryotic expression system yielded 
some successes. Though there was not much recombinant protein made in the soluble fraction 
of cell lysates, the amount present was used to immunize mice and start the screening process 
for a mAb to bovine ICAM-1, and preliminary in vitro testing showed that the recombinant 
protein to be biologically active. There is now also an ample supply of solubilized recombinant 
bovine ICAM-1 that can be utilized for further analyses. The work presented here has started 
the investigative process into the role ICAM-1 plays in bovine inflammatory diseases. 
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